Logo

Phase-1 in Toxicogenomics Service Partnership with NCI

May 05, 2003

NEW YORK, May 5 - Phase-1 Molecular Toxicology said today that it is providing toxicogenomics services for the National Cancer Institute.

 

Specifically, the company said it will analyze the toxicity of cancer treatments in comparison to the mechanism of antitumor action.

 

Phase-1 will receive animal tissues from several contract laboratories performing preclinical safety studies for the NCI and will evaluate the tissues for treatment-related gene expression effects.

 

According to Joseph Tomaszewski, chief of the toxicology and pharmacology branch at NCI, Phase-1 was chosen as NCI's service partner because "they have toxchips for the relevant species in which we perform our toxicity studies."

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.